Walleye Capital
KYNB

Walleye Capital’s Kyntra Bio KYNB Stock Holding History

Walleye Capital’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-460
Closed -$184K – 4061
2022
Q4 		$184K Buy
+460
New +$176K ﹤0.01% 2095
2019
Q4 		– Sell
-96
Closed -$89K – 1932
2019
Q3 		$89K Sell
96
-80
-45% -$87.9K 0.01% 1467
2019
Q2 		$199K Buy
+176
New +$193K 0.02% 974

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GC
GFG Capital Miami, Florida $363M AUM 45.53% 1-Year Est. Return

Walleye Capital's KYNB Position: Q3 2024 in Review

Walleye Capital sold out of Kyntra Bio (KYNB) in Q3 2024, closing a stake of 5,478 shares — an estimated $122K sold.

Walleye Capital first reported a position in KYNB in Q2 2019 and held it in 11 quarters. The position peaked at $1.95M in Q2 2022. 70 funds tracked by Wall St. Rank hold KYNB as of Q3 2024.

  • Walleye Capital reported no remaining Kyntra Bio position as of Q3 2024 after selling out during the quarter.
  • Walleye Capital sold 5,478 Kyntra Bio shares in Q3 2024, an estimated $122K.
  • Walleye Capital first reported a position in Kyntra Bio in Q2 2019 and held it in 11 quarters.
  • Walleye Capital's Kyntra Bio position peaked at $1.95M in Q2 2022.
  • 70 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.